Page last updated: 2024-11-12
ono-5334
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 11582982 |
| CHEMBL ID | 4303672 |
| SCHEMBL ID | 3629499 |
| MeSH ID | M0560831 |
Synonyms (17)
| Synonym |
|---|
| SCHEMBL3629499 |
| ono-5334 |
| n-((1s)-3-{(2z)-2-((4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene) hydrazino}-2,3-dioxo-1-(tetrahydro-2h-pyran-4-yl)propyl)cycloheptane carboxamide |
| AKOS032954060 |
| unii-9tdn93l9fn |
| HY-108044 |
| n-[(1s)-3-[(2z)-2-[(4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazinyl]-1-(oxan-4-yl)-2,3-dioxopropyl]cycloheptanecarboxamide |
| n-((1s)-3-((2z)-2-((4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene) hydrazino)-2,3-dioxo-1-(tetrahydro-2h-pyran-4-yl)propyl)cycloheptane carboxamide |
| 2h-pyran-4-propanoic acid, beta-((cycloheptylcarbonyl)amino)tetrahydro-alpha-oxo-, (2z)-2-((4r)-3,4-dimethyl-2-thiazolidinylidene)hydrazide, (betas)- |
| cid 11582982 |
| CHEMBL4303672 |
| CS-0027222 |
| MS-27868 |
| 9tdn93l9fn , |
| 620614-15-5 |
| n-((1s)-3-((2z)-2-((4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene)hydrazino)-2,3-dioxo-1-(tetrahydro-2h-pyran-4yl)propyl)cycloheptanecarboxamide |
| BO177436 |
Research Excerpts
Pharmacokinetics
The purpose of the study was to clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers. The pharmacokinetics and the pharmacodynamic effects on biochemical markers of bone turnover were investigated.
| Excerpt | Reference | Relevance |
|---|
| " The pharmacokinetics and the pharmacodynamic effects on biochemical markers of bone turnover of the new cathepsin K inhibitor, ONO-5334, were investigated in a multiple ascending dose, phase 1 study." | ( Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M, 2012) | 0.79 |
| "The purpose of the study was clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers using sustained release (SR) formulations with different pharmacokinetic (PK) patterns, and identify the optimal SR formulation." | ( Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
Deacon, S; Hashimoto, Y; Honda, N; Sekiya, N; Tanaka, M; Yamamoto, M, 2014) | 0.9 |
| " There was no significant difference in PK and pharmacodynamic potency (IC50 ) between Caucasian and Japanese." | ( Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
Deacon, S; Hasegawa, C; Honda, N; Ieiri, I; Nagase, S; Ogawa, M; Ohno, T; Ohyama, M; Small, M; Umemura, T, 2014) | 0.63 |
Dosage Studied
Morning dosing of ONO-5334 is more efficacious at reducing markers of bone turnover in healthy postmenopausal women.
| Excerpt | Relevance | Reference |
|---|
| " Multiple dosing with ONO-5334 100 mg resulted in considerable suppression of bone resorption markers with no appreciable effects on bone formation markers (B-ALP, OC) or osteoclast number (TRAP5b)." | ( Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M, 2012) | 0.9 |
| " These levels were consistently decreased below pre-dose levels by repeated oral dosing with ONO-5334 for 7 days." | ( Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Hashimoto, Y; Kawabata, K; Kawada, N; Kayasuga, R; Kunishige, A; Mori, H; Nakanishi, Y; Nishikawa, S; Ochi, Y; Sugitani, M; Tanaka, M; Yamada, H, 2011) | 0.98 |
| " Repeated SRT dosing did not significantly affect PK, although C 24h increased slightly." | ( Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M, 2015) | 0.63 |
| "Morning dosing of ONO-5334 is more efficacious at reducing markers of bone turnover in healthy postmenopausal women than evening dosing." | ( Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Deacon, S; Dijk, DJ; Eastell, R; Greenwood, A; Sharpe, J; Small, M; Tanimoto, M; Yamada, H; Yuba, M, 2016) | 1.02 |
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 16.22
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 16.22 (24.57) | | Research Supply Index | 3.47 (2.92) | | Research Growth Index | 4.51 (4.65) | | Search Engine Demand Index | 10.37 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 12 (63.16%) | 5.53% |
| Reviews | 2 (10.53%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (26.32%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |